Rapid Dose Therapeutics Corp. (RDTCF)
USD 0.18
(2150.0%)
USD 0.18
(2150.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -3.73 Million CAD | 1.83% |
| 2023 | -3.8 Million CAD | 14.13% |
| 2022 | -4.43 Million CAD | -95.42% |
| 2021 | -2.26 Million CAD | 70.19% |
| 2020 | -7.61 Million CAD | 33.69% |
| 2019 | -11.48 Million CAD | -22827.21% |
| 2018 | -50.07 Thousand CAD | -6.33% |
| 2017 | -47.09 Thousand CAD | 8.98% |
| 2016 | -51.74 Thousand CAD | -169.47% |
| 2015 | -19.2 Thousand CAD | 33.89% |
| 2014 | -29.04 Thousand CAD | 62.05% |
| 2013 | -76.53 Thousand CAD | -13.02% |
| 2012 | -67.72 Thousand CAD | 15.3% |
| 2011 | -79.95 Thousand CAD | -1074.96% |
| 2010 | -6805.00 CAD | -101.39% |
| 2009 | -3379.00 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -878.49 Thousand CAD | -57.89% |
| 2024 FY | -3.08 Million CAD | 19.04% |
| 2024 Q4 | -1.16 Million CAD | -32.15% |
| 2024 Q2 | -556.4 Thousand CAD | -19.61% |
| 2024 Q1 | -465.16 Thousand CAD | 64.27% |
| 2023 Q4 | -1.3 Million CAD | -123.14% |
| 2023 Q2 | -914.52 Thousand CAD | 9.31% |
| 2023 Q3 | -583.5 Thousand CAD | 36.2% |
| 2023 Q1 | -1 Million CAD | 54.06% |
| 2023 FY | -3.8 Million CAD | 14.13% |
| 2022 Q3 | -787.07 Thousand CAD | -13.33% |
| 2022 FY | -4.43 Million CAD | -95.42% |
| 2022 Q4 | -2.19 Million CAD | -178.88% |
| 2022 Q1 | -766.4 Thousand CAD | 6.28% |
| 2022 Q2 | -694.49 Thousand CAD | 9.38% |
| 2021 Q3 | -521.03 Thousand CAD | -12.68% |
| 2021 Q1 | -468.4 Thousand CAD | 48.86% |
| 2021 Q4 | -817.75 Thousand CAD | -56.95% |
| 2021 Q2 | -462.42 Thousand CAD | 1.28% |
| 2021 FY | -2.26 Million CAD | 70.19% |
| 2020 Q3 | -2.79 Million CAD | -283.33% |
| 2020 FY | -7.61 Million CAD | 33.69% |
| 2020 Q1 | -3.17 Million CAD | 67.15% |
| 2020 Q2 | -728.29 Thousand CAD | 77.08% |
| 2020 Q4 | -915.92 Thousand CAD | 67.19% |
| 2019 Q4 | -9.67 Million CAD | -861.6% |
| 2019 FY | -11.48 Million CAD | -22827.21% |
| 2019 Q1 | -298.51 Thousand CAD | 75.61% |
| 2019 Q2 | -504.32 Thousand CAD | -68.94% |
| 2019 Q3 | -1 Million CAD | -99.46% |
| 2018 Q3 | -19.37 Thousand CAD | 27.59% |
| 2018 Q1 | -6384.00 CAD | -61.87% |
| 2018 Q2 | -26.76 Thousand CAD | -319.2% |
| 2018 FY | -50.07 Thousand CAD | -6.33% |
| 2018 Q4 | -1.22 Million CAD | -6215.03% |
| 2017 Q4 | -3944.00 CAD | 69.64% |
| 2017 Q3 | -12.98 Thousand CAD | 21.17% |
| 2017 Q2 | -16.47 Thousand CAD | -823.14% |
| 2017 FY | -47.09 Thousand CAD | 8.98% |
| 2017 Q1 | -1785.00 CAD | 89.47% |
| 2016 Q4 | -16.94 Thousand CAD | -42.69% |
| 2016 FY | -51.74 Thousand CAD | -169.47% |
| 2016 Q3 | -11.87 Thousand CAD | 18.48% |
| 2016 Q2 | -14.57 Thousand CAD | -69.02% |
| 2016 Q1 | -8621.00 CAD | -9.28% |
| 2015 FY | -19.2 Thousand CAD | 33.89% |
| 2015 Q3 | -20.66 Thousand CAD | -175.51% |
| 2015 Q2 | 27.36 Thousand CAD | 181.78% |
| 2015 Q1 | -33.46 Thousand CAD | -308.33% |
| 2015 Q4 | -7889.00 CAD | 61.82% |
| 2014 Q2 | -13.75 Thousand CAD | -446.98% |
| 2014 Q3 | -5085.00 CAD | 63.02% |
| 2014 Q4 | -8195.00 CAD | -61.16% |
| 2014 Q1 | -2514.00 CAD | 74.14% |
| 2014 FY | -29.04 Thousand CAD | 62.05% |
| 2013 Q4 | -9723.00 CAD | -217.85% |
| 2013 FY | -76.53 Thousand CAD | -13.02% |
| 2013 Q1 | -32.98 Thousand CAD | -94.83% |
| 2013 Q2 | -21.51 Thousand CAD | 34.76% |
| 2013 Q3 | -3059.00 CAD | 85.78% |
| 2012 Q1 | -7582.00 CAD | 38.6% |
| 2012 Q2 | -36.89 Thousand CAD | -386.65% |
| 2012 Q3 | -5105.00 CAD | 86.16% |
| 2012 Q4 | -16.92 Thousand CAD | -231.62% |
| 2012 FY | -67.72 Thousand CAD | 15.3% |
| 2011 Q3 | -10.89 Thousand CAD | 23.08% |
| 2011 Q4 | -12.34 Thousand CAD | -13.39% |
| 2011 FY | -79.95 Thousand CAD | -1074.96% |
| 2011 Q1 | -7050.00 CAD | 86.91% |
| 2011 Q2 | -14.15 Thousand CAD | -100.82% |
| 2010 Q3 | -4886.00 CAD | -142.0% |
| 2010 Q1 | -1225.00 CAD | 40.1% |
| 2010 FY | -6805.00 CAD | -101.39% |
| 2010 Q4 | -53.86 Thousand CAD | -1002.37% |
| 2010 Q2 | -2019.00 CAD | -64.82% |
| 2009 Q4 | -2045.00 CAD | 54.72% |
| 2009 Q3 | -4516.00 CAD | 0.0% |
| 2009 FY | -3379.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioxytran, Inc. | -3.82 Million USD | 2.13% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 94.792% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1328.51% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.069% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -31.162% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 79.051% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 104.568% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -143.402% |
| Marizyme, Inc. | -34.08 Million USD | 89.031% |
| Genus plc | 6.4 Million USD | 158.418% |
| Pharming Group N.V. | -4.87 Million USD | 23.378% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -88.211% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -301.424% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 55.224% |
| ContraFect Corporation | -56.88 Million USD | 93.428% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -166.677% |
| IMV Inc. | -38.67 Million USD | 90.332% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -35.914% |
| ONE Bio Corp. | 13.68 Million USD | 127.327% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 93.662% |
| Mesoblast Limited | -84.14 Million USD | 95.557% |
| MultiCell Technologies, Inc. | -722.81 USD | -517156.402% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 205.615% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.101% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -859.72% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -42.293% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 176.072% |
| Biomind Labs Inc. | -1 Million USD | -270.322% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -28.868% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 43.761% |
| Skye Bioscience, Inc. | -13.67 Million USD | 72.653% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -100.539% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 138.376% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -12382.575% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 17.914% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 25.884% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 76.441% |
| Accustem Sciences Inc. | -3.74 Million USD | 0.204% |
| EV Biologics, Inc. | -483.06 Thousand USD | -673.975% |
| Q BioMed Inc. | -3.44 Million USD | -8.508% |
| GB Sciences, Inc. | -1.42 Million USD | -163.2% |
| Alpha Cognition Inc. | -9.7 Million USD | 61.478% |
| CSL Limited | 3.7 Billion USD | 100.101% |
| Agentix Corp. | -1.37 Million USD | -172.554% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 93.199% |
| Enzolytics Inc. | -2.14 Million USD | -73.994% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Resverlogix Corp. | -12.74 Million USD | 70.674% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -18.007% |
| MetaStat, Inc. | - USD | Infinity% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -93.458% |
| argenx SE | -425.04 Million USD | 99.12% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 93.264% |
| HST Global, Inc. | -140.9 Thousand USD | -2553.368% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -258.121% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -232.364% |
| Halberd Corporation | -75.05 Thousand USD | -4881.72% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -28.065% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -9.803% |
| Zenith Capital Corp. | -8.94 Million USD | 58.193% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -136.728% |
| GeneThera, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -52.273% |
| AVAX Technologies, Inc. | 6.69 Million USD | 155.862% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2079.926% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -86.495% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -21361.346% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -2.46 Million USD | -51.566% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -279.937% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -197.674% |
| Kadimastem Ltd | -3.04 Million USD | -22.976% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 51.937% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1960.105% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -179.968% |
| LadRx Corporation | -3.82 Million USD | 2.219% |
| Cell Source, Inc. | -4.32 Million USD | 13.561% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -799.872% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -444.258% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -444.258% |
| Affymax, Inc. | -15.04 Million USD | 75.151% |
| Mobile Lads Corp. | -554.55 Thousand USD | -574.201% |
| Itoco Inc. | -919.14 Thousand USD | -306.769% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 11.788% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -234.118% |
| International Stem Cell Corporation | -663 Thousand USD | -463.919% |
| CytoDyn Inc. | -18.05 Million USD | 79.296% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -14754.116% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1598.844% |
| Qrons Inc. | -643.67 Thousand USD | -480.847% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -562.056% |
| SYBLEU INC | -149.18 Thousand USD | -2406.221% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -67.667% |
| Rebus Holdings, Inc. | -664 Thousand USD | -463.069% |
| GlobeImmune, Inc. | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -105.844% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -7002.547% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -18281.421% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 89.691% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -131.074% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -408.1% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -20.179% |
| Neutra Corp. | -229.48 Thousand USD | -1529.198% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 78.683% |
| PureTech Health plc | -146.19 Million USD | 97.443% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 82.603% |
| IXICO plc | -1.43 Million USD | -160.18% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 60.607% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.931% |
| CSL Limited | 3.81 Billion USD | 100.098% |
| Cellectis S.A. | -108.85 Million USD | 96.565% |